Skip to main content

Advertisement

SpringerLink
Log in

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Several adipocytokines, such as leptin or adiponectin, are associated with obesity and the risk for breast cancer. Adiopcyte fatty acid binding-protein (A-FABP) is another protein found in adipose tissue; therefore, we investigated the association of A-FABP with the occurrence and prognosis of breast cancer. In our study, 200 women attending the University of Ulm for breast surgery between the years 2005 and 2007 were included; 159 had histologically confirmed breast cancer; 41 had histologically confirmed benign lesions. Serum levels of A-FABP, leptin, and adiponectin were measured, and their relationship to body-mass-index (BMI), breast cancer, and tumor characteristics were analyzed; logistic regression model was adjusted to age, BMI, menopausal status, use of Hormone Replacement Therapy (HRT), and family history of breast cancer. Serum A-FABP levels were found to be significantly higher in obese (BMI ≥ 25) than in non-obese women (BMI ≤ 24.9), 41.16 ng/ml and 24.95 ng/ml, respectively (P < 0.0001). Independent of obesity, the serum A-FABP levels were significantly higher in breast cancer patients (34.65 ng/ml) than in healthy controls (24.47 ng/ml), P < 0.0001; the odds ratio (1.038, P < 0.05, 95% confidence interval 1.001–1.72) showed a significant association of A-FABP with breast cancer risk. Serum leptin levels showed a strong correlation with BMI (r s = 0.78) and were significantly higher in breast cancer patients (20.87 ng/ml) than in controls (14.90 ng/ml), P < 0.05. In contrast, adiponectin showed no significant association with breast cancer. Concerning tumor characteristics, A-FABP was positively connected with tumor size (T ≥ 2 cm, P < 0.05) and nodal-status (P < 0.05). Our study reveals that high A-FABP serum levels are associated with obesity, breast cancer risk, and adverse tumor characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pignatelli M, Cocca C, Santos A, Perez-Castillo A (2003) Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene 22:5446–5450

    Article  CAS  PubMed  Google Scholar 

  2. Housa D, Housova J, Vernerova Z, Haluzik M (2006) Adipocytokines and cancer. Physiol Res 55:233–244

    CAS  PubMed  Google Scholar 

  3. Lorincz A, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13:279–292

    Article  CAS  PubMed  Google Scholar 

  4. Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762–771

    Article  CAS  PubMed  Google Scholar 

  5. van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514–527

    Article  PubMed  Google Scholar 

  6. Rose D, Komninou D, Stephenson G (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153–165

    Article  CAS  PubMed  Google Scholar 

  7. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JMP, Ashworth A, Peto J, Silva IDS (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19

    CAS  PubMed  Google Scholar 

  8. Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Rel Cancer 14:189–206

    Article  CAS  Google Scholar 

  9. Rohner-Jeanrenaud F, Jeanrenaud B (1996) The discovery of leptin and its impact in the understanding of obesity. Eur J Endocrinol/European Federation of Endocrine Societies 135:649–650

    CAS  Google Scholar 

  10. Ishikawa M, Kitayama J, Nagawa H (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10:4325–4331

    Article  CAS  PubMed  Google Scholar 

  11. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9:5699–5704

    CAS  PubMed  Google Scholar 

  12. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107

    Article  CAS  PubMed  Google Scholar 

  13. Möhlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfüller B, Arafat AM, Pfeiffer AFH, Schöfl C (2007) Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol/European Federation of Endocrine Societies 157:195–200

    Google Scholar 

  14. Boord JB, Fazio S, Linton MF (2002) Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 13:141–147

    Article  CAS  PubMed  Google Scholar 

  15. Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M (2005) Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Therap Oncol 5:133–143

    CAS  Google Scholar 

  16. Li H, Lu Q, Dong L, Xue H, Zhou H, Yang H (2007) Expression of fatty acid binding protein in human breast cancer tissues. Chin J Cell Mol Immunol 23:312–316. (in Chinese by Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)

    Google Scholar 

  17. Swanson CA, Coates RJ, Schoenberg JB, Malone KE, Gammon MD, Stanford JL, Shorr IJ, Potischman NA, Brinton LA (1996) Body size and breast cancer risk among women under age 45 years. Am J Epidemiol 143:698–706

    CAS  PubMed  Google Scholar 

  18. Franceschi S, Favero A, La Vecchia C, Barón AE, Negri E, Dal Maso L, Giacosa A, Montella M, Conti E, Amadori D (1996) Body size indices and breast cancer risk before and after menopause. Int J Cancer 67:181–186

    Article  CAS  PubMed  Google Scholar 

  19. van den Brandt PA, Dirx MJ, Ronckers CM, van den Hoogen P, Goldbohm RA (1997) Height, weight change, and postmenopausal breast cancer risk: the Netherlands Cohort Study. Cancer Causes Control 8:39–47

    Article  PubMed  Google Scholar 

  20. Montazeri A, Sadighi J, Farzadi F, Maftoon F, Vahdaninia M, Ansari M, Sajadian A, Ebrahimi M, Haghighat S, Harirchi I (2008) Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case–control study. BMC Cancer 8:278

    Article  PubMed  Google Scholar 

  21. Trentham-Dietz A, Newcomb PA, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Stampfer M, Willett WC (2000) Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11:533–542

    Google Scholar 

  22. Hou W, Xu Y, Yu T, Zhang L, Zhang W, Fu C, Sun Y, Wu Q, Chen L (2007) Adipocytokines and breast cancer risk. Chin Med J 120:1592–1596

    CAS  PubMed  Google Scholar 

  23. Rosenberg L, Czene K, Hall P (2009) Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy. Br J Cancer 100(9):1486–1491

    Article  CAS  PubMed  Google Scholar 

  24. Das R, Hammamieh R, Neill R, Melhem M, Jett M (2001) Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res 7:1706–1715

    CAS  PubMed  Google Scholar 

  25. Ohlsson G, Moreira JMA, Gromov P, Sauter G, Celis JE (2005) Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4:570–581

    Article  CAS  PubMed  Google Scholar 

  26. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NMS, Wong WK, Lam KSL (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52:405–413

    Article  CAS  PubMed  Google Scholar 

  27. Stejskal D, Karpisek M (2006) Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Investig 36:621–625

    Article  CAS  Google Scholar 

  28. Yeung DCY, Xu A, Cheung CWS, Wat NMS, Yau MH, Fong CHY, Chau MT, Lam KSL (2007) Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 27:1796–1802

    Article  CAS  PubMed  Google Scholar 

  29. Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY (2009) Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 32:147–152

    Article  CAS  PubMed  Google Scholar 

  30. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D (2000) Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11:383–388

    Article  CAS  PubMed  Google Scholar 

  31. Ozet A, Arpaci F, Yilmaz MI, Ayta H, Ozturk B, Komurcu S, Yavuz AA, Tezcan Y, Acikel C (2001) Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol 31:424–427

    Article  CAS  PubMed  Google Scholar 

  32. Coskun U, Günel N, Toruner FB, Sancak B, Onuk E, Bayram O, Cengiz O, Yilmaz E, Elbeg S, Ozkan S (2003) Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 50:41–46

    CAS  PubMed  Google Scholar 

  33. Sauter ER, Garofalo C, Hewett J, Hewett JE, Morelli C, Surmacz E (2004) Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer. Horm Metab Res 36:336–340

    Article  CAS  PubMed  Google Scholar 

  34. Woo H, Park H, Ki C, Park YL, Bae WG (2006) Relationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea. Cancer Lett 237:137–142

    Article  CAS  PubMed  Google Scholar 

  35. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, Argiles JM, Benedetto C (2004) Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 24:1529–1535

    CAS  PubMed  Google Scholar 

  36. Chen D, Chung Y, Yeh Y, Chaung H, Kuo F, Fu O, Chen H, Hou M, Yuan SF (2006) Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237:109–114

    Article  CAS  PubMed  Google Scholar 

  37. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5:421–426

    CAS  PubMed  Google Scholar 

  38. Han C, Zhang H, Du L, Liu X, Jing J, Zhao X, Yang X, Tian B (2005) Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine 26:19–24

    Article  CAS  PubMed  Google Scholar 

  39. Cento RM, Proto C, Spada RS, Napolitano V, Ciampelli M, Cucinelli F, Lanzone A (1999) Leptin levels in menopause: effect of estrogen replacement therapy. Horm Res 52:269–273

    Article  CAS  PubMed  Google Scholar 

  40. Hayase H, Nomura S, Abe T, Izawa T (2002) Relation between fat distributions and several plasma adipocytokines after exercise training in premenopausal and postmenopausal women. J Physiol Anthropol Appl Hum Sci 21:105–113

    Article  Google Scholar 

  41. Riad-Gabriel MG, Jinagouda SD, Sharma A, Boyadjian R, Saad MF (1998) Changes in plasma leptin during the menstrual cycle. Eur J Endocrinol/European Federation of Endocrine Societies 139:528–531

    CAS  Google Scholar 

  42. Cella F, Giordano G, Cordera R (2000) Serum leptin concentrations during the menstrual cycle in normal-weight women: effects of an oral triphasic estrogen-progestin medication. Eur J Endocrinol/European Federation of Endocrine Societies 142:174–178

    CAS  Google Scholar 

  43. Geisthövel F, Jochmann N, Widjaja A, Horn R, Brabant G (2004) Serum pattern of circulating free leptin, bound leptin, and soluble leptin receptor in the physiological menstrual cycle. Fertil Steril 81:398–402

    Article  PubMed  Google Scholar 

  44. Stattin P, Söderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, Olsson T (2004) Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat 86:191–196

    Article  CAS  PubMed  Google Scholar 

  45. Gröschl M, Wagner R, Dörr HG, Blum W, Rascher W, Dötsch J (2000) Variability of leptin values measured from different sample matrices. Horm Res 54:26–31

    Article  PubMed  Google Scholar 

  46. Steffes MW, Gross MD, Schreiner PJ, Yu X, Hilner JE, Gingerich R, Jacobs DR (2004) Serum adiponectin in young adults—interactions with central adiposity, circulating levels of glucose, and insulin resistance: the CARDIA study. Ann Epidemiol 14:492–498

    Article  PubMed  Google Scholar 

  47. Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME (2009) Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Front Biosci (schol Ed) 1:329–357

    Google Scholar 

  48. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15:875–884

    Article  CAS  PubMed  Google Scholar 

  49. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med 348:1625–1638

    Article  PubMed  Google Scholar 

  50. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N (2005) Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23:6037–6042

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Statistical analyses were reviewed by Mrs. Hay and Mrs. Gerstner, official staff of the biometric institute of the University of Ulm.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany

    K. Hancke, D. Grubeck, R. Kreienberg & J. M. Weiss

  2. Hospital of Gynaecology and Obstetrics, Kantonsspital Baden, Switzerland

    N. Hauser

Authors
  1. K. Hancke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Grubeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Hauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. M. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Hancke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hancke, K., Grubeck, D., Hauser, N. et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 119, 367–377 (2010). https://doi.org/10.1007/s10549-009-0577-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0577-9

Keywords

Search

Navigation